Memantine augmentation of escitalopram in treatment of executive function among patients with obsessive-compulsive disorder (OCD): a double-blind placebo-controlled randomized clinical trial

Authors

Institutions

Publication Details

Journal
BMC Psychiatry
Published
2025-06-02
DOI
https://doi.org/10.1186/s12888-025-06856-7
Citations
3
Primary Topic
Obsessive-Compulsive Spectrum Disorders
Type
article
Field-Weighted Citation Impact
6.92
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Memantine augmentation of escitalopram in treatment of executive function among patients with obsessive-compulsive disorder (OCD): a double-blind placebo-controlled randomized clinical trial

Leila Razeghian Jahromi, Reza Moshfeghinia, Mohammadsadegh Kamran, Hasan Mirzazadeh et al.
3 citations
BMC Psychiatry
Obsessive-Compulsive Spectrum Disorders
6.92
article

Memantine augmentation of escitalopram in treatment of executive function among patients with obsessive-compulsive disorder (OCD): a double-blind placebo-controlled randomized clinical trial

Leila Razeghian Jahromi, Reza Moshfeghinia, Mohammadsadegh Kamran, Hasan Mirzazadeh, Younes Ghaeminia, Amin Mohamad Niaei
article en
3 citations

Abstract

No abstract available for this paper.
BMC PsychiatryVol. 25(1)
Shiraz University of Medical Sciences (IR), Lorestan University of Medical Sciences (IR), Fasa University of Medical Sciences (IR)
Openalex Percentile: Top 4%
Obsessive-Compulsive Spectrum Disorders
6.92
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.